Axios Vitals on MSN4h
FDA approves Vertex non-opioid pain drug
The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...
3 Magnificent Stocks to Buy and Hold Forever
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
StudyFinds on MSN19h
Journavx: What to know about new FDA-approved non-opioid pain medication
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
Hosted on MSN30m
Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?
Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
GEN3h
Top 10 Takeover Targets of 2025
Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...
New sickle cell treatment approved for NHS use offers patients ‘hope of a cure’
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...